Viral membranes: An emerging antiviral target for enveloped viruses?

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 6, 2010, Pages 635-638

  Song, Jae Min ^a   Seong, Baik Lin ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yonsei University   (South Korea)

Author keywords

Antiviral resistance; Broad spectrum; Enveloped virus; Fusion; Lipid membrane; Rhodanine derivative; Viral entry inhibitor

Indexed keywords

LIPOSOME; LJ 001; RHODANINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CELL MEMBRANE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS A; LIPID MEMBRANE; MEMBRANE BINDING; NIPAH VIRUS; NONHUMAN; NOTE; RIFT VALLEY FEVER; STRUCTURE ACTIVITY RELATION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS VIRULENCE;

EID: 77953262931     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.51     Document Type: Note

References (27)

1. Cohen J. Swine flu pandemic. What's old is new: 1918 virus matches 2009 H1N1 strain. Science 327(5973), 1563-1564 (2010).
2. Guan Y, Poon LL, Cheung CY et al. H5N1 influenza: a protean pandemic threat. Proc. Natl Acad. Sci. USA 101(21), 8156-8161 (2004).
3. World Health Organization. WHO guidelines of the use of vaccines and antivirals during influenza pandemics. WHO, Geneva, Switzerland (2004).
4. Stacy L. Biological Threat and Terrorism: Assessing the Science and Response Capabilities. Forum on Emerging Infections. National Academic Press, Washington, DC, USA, 176 (2002).
5. Gaudioso J, Salerno RM. Science and government. Biosecurity and research: minimizing adverse impacts. Science 305(5681), 180 (2004).
6. Kim CU, Lew W, Williams MA et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119(4), 681-690 (1997).
7. Sy CL, Lee SS, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg. Infect. Di. 16(4), 723-725 (2010).
8. Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85(1), 59-74 (2010).
9. Crotty S, Maag D, Arnold JJ et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6(12), 1375-1379 (2000).
10. Crotty S, Cameron C, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. 80(2), 86-95 (2002).
11. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve. Clin. J. Med. 71(Suppl. 3), S17-S21 (2004).
12. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 78(1), 91-102 (2008).
13. Gowen BB, Wong MH, Jung KH et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51(9), 3168-3176 (2007).
14. Song JM, Seong BL. Tea catechins as a potential alternative anti-infectious agent. Expert Rev. Anti Infect. Ther. 5(3), 497-506 (2007).
15. Wolf MC, Freiberg AN, Zhang T et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA 107(7), 3157-3162 (2010).
16. Jouvenet N, Neil SJ, Zhadina M et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83(4), 1837-1844 (2009).
17. Lara HH, Ayala-Nunez NV, Ixtepan- Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnology 8, 1 (2010).
18. O'Keefe BR, Vojdani F, Buffa V et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl Acad. Sci. USA 106(15), 6099-6104 (2009).
19. O'Keefe BR, Giomarelli B, Barnard DL et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol. 84(5), 2511-2521 (2010).
20. Larson RA, Dai D, Hosack VT et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82(21), 10768-10775 (2008).
21. Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR. Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology 388(2), 248-259 (2009).
22. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80(24), 11960-11967 (2006).
23. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 68(2), 66-74 (2005).
24. Song JM, Park KD, Lee KH et al. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res. 76(2), 178-185 (2007).
25. Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol. 6(10), 995-1001 (2005).
26. Kotwal GJ, Kaczmarek JN, Leivers S et al. Anti-HIV, anti-poxvirus, and anti-SARS activity of a nontoxic, acidic plant extract from the Trifollium species Secomet-V/ anti-vac suggests that it contains a novel broad-spectrum antiviral. Ann. NY Acad. Sci. 1056, 293-302 (2005).
27. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321(25), 1696-1702 (1989).